Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Novabridge Biosciences ADR (NBP)

Novabridge Biosciences ADR (NBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 459,911
  • Shares Outstanding, K 115,266
  • Annual Sales, $ 0 K
  • Annual Income, $ -22,230 K
  • EBIT $ -40 M
  • EBITDA $ -39 M
  • 60-Month Beta 1.63
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.59

Options Overview Details

View History
  • Implied Volatility 213.49% (+14.05%)
  • Historical Volatility 70.86%
  • IV Percentile 32%
  • IV Rank 18.24%
  • IV High 522.60% on 11/07/25
  • IV Low 144.53% on 11/25/25
  • Expected Move (DTE 14) 1.02 (25.25%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 4
  • Volume Avg (30-Day) 47
  • Put/Call OI Ratio 0.60
  • Today's Open Interest 2,862
  • Open Int (30-Day) 3,666
  • Expected Range 3.02 to 5.06

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/25
See More
  • Average Estimate -0.06
  • Number of Estimates 3
  • High Estimate -0.05
  • Low Estimate -0.08
  • Prior Year -0.25
  • Growth Rate Est. (year over year) +76.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.60 +13.19%
on 12/03/25
4.71 -13.48%
on 11/20/25
-0.19 (-4.34%)
since 11/05/25
3-Month
3.20 +27.34%
on 09/10/25
6.79 -39.99%
on 10/16/25
-0.31 (-6.96%)
since 09/05/25
52-Week
0.60 +584.87%
on 04/04/25
6.79 -39.99%
on 10/16/25
+3.02 (+288.10%)
since 12/05/24

Most Recent Stories

More News
NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO

Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or refractory to checkpoint inhibitors, a multi-billion dollar drug class hampered by widespread resistance...

NBP : 4.16 (+4.26%)
NovaBridge’s Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward

Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 Program The...

FDMT : 10.85 (-3.04%)
NBP : 4.16 (+4.26%)
AURA : 6.48 (+0.47%)
Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders

Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders

NBP : 4.16 (+4.26%)
NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries

NovaBridge subsidiary Visara assigned its exclusive license to Everest Medicines to accelerate the development of potential best-in-class therapy for wet AMD, VIS-101, leveraging Everest Medicines’ strong...

NBP : 4.16 (+4.26%)
I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform

New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative medicines for patients worldwide Strategy centers on broadening access to global capital...

IMAB : 4.63 (-0.22%)
NBP : 4.16 (+4.26%)

Business Summary

NovaBridge Biosciences is a biotechnology platform company committed to accelerating access to innovative medicines. NovaBridge Biosciences, formerly known as I-MAB, is based in ROCKVILLE, Md.

See More

Key Turning Points

3rd Resistance Point 4.42
2nd Resistance Point 4.26
1st Resistance Point 4.12
Last Price 4.16
1st Support Level 3.82
2nd Support Level 3.66
3rd Support Level 3.52

See More

52-Week High 6.79
Fibonacci 61.8% 4.42
Last Price 4.16
Fibonacci 50% 3.69
Fibonacci 38.2% 2.96
52-Week Low 0.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar